VERACYTE, INC. VCYT
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.
Through our leading portfolio of comprehensive molecular diagnostic tests, we are focused on progressing patient care from the current standard to a more individualized approach, leveraging each patient's unique cancer biology to improve their outcomes. We serve global markets with two complementary models. In the United States, we offer laboratory developed tests, or LDTs, through our centralized Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology expertise in Austin, Texas. Outside of the United States, we provide in vitro diagnostic, or IVD, tests to patients through distribution to laboratories and hospitals that can perform the tests locally. In the United States, we currently offer tests in prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). Our international distribution of IVDs is currently focused on our Prosigna test and, in the future, we intend to offer Decipher Prostate as an IVD.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- International
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $496.6M | $423.5M | $334.5M |
| International | $20.5M | $22.2M | $26.5M |
As the company reported it, from the “Segment - Revenue by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M | $117.5M | $120.4M | $92.0M | $72.0M | $65.1M |
| Cost of revenue | — | — | — | — | — | — | $36.1M | $33.1M | $28.2M | $25.5M |
| Gross profit | $362.5M | $298.1M | $229.7M | $175.7M | — | — | $84.3M | $58.9M | $43.8M | $39.6M |
| R&D | $70.8M | $69.3M | $57.3M | $40.6M | $29.8M | $17.2M | $14.9M | $14.8M | $13.9M | $15.3M |
| SG&A | $110.8M | $110.6M | $86.2M | $73.2M | $101.4M | $36.7M | $29.0M | $24.0M | $23.1M | $23.8M |
| Total operating expenses | $304.8M | $282.0M | $315.5M | $216.8M | $301.4M | $152.9M | $135.5M | $114.2M | $98.5M | $93.9M |
| Operating income | $57.8M | $16.1M | -$85.8M | -$41.1M | -$81.9M | -$35.4M | -$15.1M | -$22.2M | -$26.5M | -$28.8M |
| Interest expense | — | — | — | — | — | $229.0K | $677.0K | $2.0M | $4.9M | $2.8M |
| Pre-tax income | $68.2M | $25.7M | -$76.6M | -$36.4M | -$81.6M | -$34.9M | -$12.6M | -$23.0M | -$31.0M | -$31.4M |
| Income tax | $1.8M | $1.6M | $2.2M | $133.0K | $6.1M | $0 | $0 | $0 | $0 | $0 |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M | -$75.6M | -$34.9M | -$12.6M | -$23.0M | — | — |
| EPS, basic | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | — | — | — |
| EPS, diluted | 0.82 | 0.31 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 |
| Shares, diluted (wtd. avg.) | 80.6M | 78.2M | 72.6M | 71.5M | 67.9M | 53.2M | 46.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $362.6M | $239.1M | $216.5M | $155.0M | $173.9M | $350.0M | $159.9M | $78.6M | $34.5M | $59.9M |
| Receivables | $44.7M | $46.5M | $40.4M | $44.0M | $41.5M | $18.5M | $19.3M | $13.2M | $12.7M | $8.8M |
| Inventory | $20.5M | $21.8M | $16.1M | $14.3M | $11.2M | $4.7M | $6.8M | $3.4M | $5.3M | $3.5M |
| Total current assets | $488.4M | $372.3M | $285.6M | $248.6M | $243.1M | $375.7M | $187.7M | $97.0M | $53.9M | $73.6M |
| Property, plant and equipment | — | — | — | $17.7M | $15.1M | $9.0M | $8.9M | $8.9M | $9.7M | $11.5M |
| Goodwill | $767.2M | $745.8M | $703.0M | $695.9M | $707.9M | $2.7M | $2.7M | $1.1M | $1.1M | $1.1M |
| Other intangibles | $89.1M | $102.3M | $88.6M | $174.9M | $202.7M | $59.9M | $65.0M | $12.0M | $13.1M | $14.1M |
| Total assets | $1.41B | $1.30B | $1.11B | $1.16B | $1.19B | $457.2M | $275.2M | $120.6M | $78.7M | $101.0M |
| Accounts payable | $4.6M | $8.6M | $12.9M | $11.9M | $12.4M | $3.1M | $2.3M | $2.5M | $3.9M | $2.4M |
| Short-term debt | — | — | — | $0 | $1.1M | $0 | $0 | $1.4M | $0 | — |
| Total current liabilities | $59.9M | $78.6M | $61.2M | $62.6M | $64.2M | $16.8M | $17.5M | $13.1M | $12.0M | $11.5M |
| Long-term debt | — | — | — | — | $0 | $810.0K | $694.0K | $23.9M | $24.9M | $24.9M |
| Total liabilities | $96.4M | $124.1M | $70.8M | $81.2M | $91.3M | $35.9M | $35.8M | $40.9M | $41.4M | $41.5M |
| Retained earnings | -$377.6M | -$444.0M | -$468.1M | -$393.7M | -$357.2M | -$281.6M | -$246.7M | -$234.1M | -$211.1M | -$180.1M |
| Total equity | $1.31B | $1.18B | $1.04B | $1.08B | $1.10B | $421.2M | $239.5M | $79.8M | $37.2M | $59.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $136.3M | $75.1M | $44.2M | $7.5M | -$31.6M | -$9.7M | -$3.2M | -$13.5M | -$23.9M | -$28.0M |
| Depreciation and amortisation | $21.4M | $23.5M | $27.2M | $25.9M | $19.6M | $7.9M | $4.1M | $3.9M | $3.8M | $3.5M |
| Stock-based compensation | $43.6M | $36.2M | $33.1M | $26.7M | $22.5M | $13.0M | $9.8M | $6.0M | $6.6M | $6.4M |
| Capital expenditure | $9.7M | $11.3M | $10.0M | $8.5M | $5.4M | $2.8M | $2.8M | $1.9M | $1.8M | $4.2M |
| Investing cash flow | -$9.2M | -$56.3M | $15.1M | -$29.4M | -$739.2M | -$3.8M | -$42.7M | -$1.9M | -$1.3M | -$4.2M |
| Financing cash flow | -$4.2M | $4.9M | $2.8M | $3.5M | $596.3M | $203.6M | $127.3M | $59.5M | -$218.0K | $52.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001384101-26-000021.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.1M | $72.0M | $92.0M | $120.4M | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Gross profit | $39.6M | $43.8M | $58.9M | $84.3M | — | — | $175.7M | $229.7M | $298.1M | $362.5M |
| Net income | — | — | -$23.0M | -$12.6M | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |